Femcord

Estrogen receptor +ve, locally advanced or metastatic breast cancer in postmenopausal women not previously treated w/ endocrine therapy or w/ disease relapse on or after adjuvant antiestrogen therapy or disease progression on antiestrogen therapy. In combination w/ palbociclib or abemaciclib for hormone receptor (HR) +ve, human epidermal growth factor receptor 2 (HER2) -ve locally advanced or metastatic breast cancer in women w/ disease progression following endocrine therapy. In combination w/ ribociclib for HR +ve, HER2 -ve locally advanced or metastatic breast cancer in postmenopausal women as initial endocrine based therapy or following disease progression on endocrine therapy.

IM Adult female including elderly 500 mg at 1-mth intervals w/ an additional 500 mg given 2 wk after initial dose. Administer as 2 consecutive 5 mL inj by slow IM (1-2 min/inj), 1 in each buttock (gluteal area).

Hypersensitivity. Severe hepatic impairment. Pregnancy & lactation.

Cancer Hormone Therapy

L02BA03 - fulvestrant ; Belongs to the class of anti-estrogens. Used in treatment of neoplastic diseases.

POM